ALNY
$225.00-2.48%
as of close, Oct 21, 2026
☾ AH $225.00 -2.48%
ALNY SEC filings (2026)
CIK 1178670 · Pharmaceutical Preparations (SIC 2834) · fiscal year ends in December
1,664 filings on EDGAR since 2002 · 22 annual, 69 quarterly, 280 current · financial statements · earnings
Latest 10-K
Feb 12, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Jul 30, 2026
quarter to Jun 30, 2026
Latest 8-K
Jul 30, 2026
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Last earnings release
Jul 30, 2026
$1.21 vs $1.44 · ▼ 28.3%
Filings on file
1,664
since 2002, 975 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
July 2026
June 2026
May 2026
April 2026
- Apr 30EarningsEarnings release — EPS $1.51 vs $0.91 est. (+65.9%); revenue $1.17B (+96% y/y) 2.8%
- Apr 30ReportQuarterly report, Q1 2026 — revenue $1.17B (+96% y/y), net income $206.0M, EPS $1.51
- Apr 6Insider saleMcLaughlin Melissa (Chief Human Resources Officer) sold 2,286 shares for $755K at $320.14–$333.94 under a 10b5-1 plan
- Apr 6ProxyProxy · Annual report to shareholders
- Apr 6ProxyProxy · Additional proxy materials
- Apr 6ProxyProxy · Proxy statement
- Apr 2Insider saleMcLaughlin Melissa (Chief Human Resources Officer) sold 1,624 shares for $519K at $316.61–$325.49 under a 10b5-1 plan
March 2026
- Mar 5Insider saleGarg Pushkal (EVP Chief R&D) sold 2,404 shares for $779K at $322.33–$326.08 under a 10b5-1 plan
- Mar 5Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 658 shares for $213K at $321.81–$326.24 under a 10b5-1 plan
- Mar 4Insider saleGreenstreet Yvonne (Chief Executive Officer · Director) sold 2,933 shares for $948K at $319.03–$325.67
- Mar 4Insider salePoulton Jeffrey V. (EVP, Chief Financial Officer) sold 2,468 shares for $797K at $319.03–$325.67
- Mar 4Insider saleTanguler Tolga (EVP, Chief Commercial Officer) sold 2,309 shares for $746K at $319.03–$325.67
- Mar 4Insider saleGarg Pushkal (EVP Chief R&D) sold 2,309 shares for $746K at $319.03–$325.67 under a 10b5-1 plan
- Mar 4Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 633 shares for $205K at $319.03–$325.67 under a 10b5-1 plan
- Mar 48-K8-K · Directors or officers; compensation
- Mar 3Insider saleGarg Pushkal (EVP Chief R&D) sold 1,775 shares for $568K at $316.74–$321.50 under a 10b5-1 plan
- Mar 3Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 1,652 shares for $528K at $316.55–$321.58 under a 10b5-1 plan
- Mar 2Insider saleGreenstreet Yvonne (Chief Executive Officer · Director) sold 6,799 shares for $2.2M at $323.62–$332.64
- Mar 2Insider salePoulton Jeffrey V. (EVP, Chief Financial Officer) sold 2,206 shares for $723K at $323.62–$332.64
- Mar 2Insider saleGarg Pushkal (EVP Chief R&D) sold 1,717 shares for $563K at $323.62–$332.64 under a 10b5-1 plan
- Mar 2Insider saleTanguler Tolga (EVP, Chief Commercial Officer) sold 1,598 shares for $524K at $323.62–$332.64
- Mar 2Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 1,598 shares for $524K at $323.62–$332.64 under a 10b5-1 plan
February 2026
- Feb 27Insider saleGarg Pushkal (EVP Chief R&D) sold 4,627 shares for $1.5M at $328.92–$334.39 under a 10b5-1 plan
- Feb 17Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 2,041 shares for $678K at $331.96 under a 10b5-1 plan
- Feb 13Insider saleGreenstreet Yvonne (Chief Executive Officer · Director) sold 6,958 shares for $2.2M at $310.08
- Feb 13Insider salePoulton Jeffrey V. (EVP, Chief Financial Officer) sold 2,242 shares for $695K at $310.08
- Feb 13Insider saleGarg Pushkal (EVP Chief R&D) sold 2,242 shares for $695K at $310.08
- Feb 13Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 1,959 shares for $607K at $310.08 under a 10b5-1 plan
- Feb 13Insider saleTanguler Tolga (EVP, Chief Commercial Officer) sold 1,959 shares for $607K at $310.08
- Feb 12EarningsEarnings release — EPS $0.82 vs $0.81 est. (+9.3%); revenue $1.10B (+85% y/y) 4.3%
- Feb 12ReportAnnual report, FY2025 — revenue $3.71B (+65% y/y), net income $313.7M, EPS $2.33
January 2026
- Jan 13Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 2,290 shares for $848K at $367.52–$374.33 under a 10b5-1 plan
- Jan 12Insider saleGreenstreet Yvonne (Chief Executive Officer · Director) sold 9,577 shares for $3.5M at $353.95–$377.82
- Jan 12Insider salePoulton Jeffrey V. (EVP, Chief Financial Officer) sold 2,780 shares for $1.0M at $353.95–$377.82
- Jan 12Insider saleGarg Pushkal (EVP Chief R&D) sold 1,510 shares for $548K at $353.95–$377.82
- Jan 12Insider saleFitzgerald Kevin Joseph (CSO & EVP, Head of Research) sold 1,510 shares for $548K at $353.95–$377.82 under a 10b5-1 plan
- Jan 12Insider saleTanguler Tolga (EVP, Chief Commercial Officer) sold 1,510 shares for $548K at $353.95–$377.82
- Jan 128-K8-K · Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient ImpactResults of operations
December 2025
- Dec 118-K8-K · Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027Other events
- Dec 38-K8-K · Alnylam Pharmaceuticals Announces Changes to Board of DirectorsDirectors or officers; compensation
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $26.9M in 31 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 2, 2026Form 4 | SUPRAN BRYANEVP, CLO and SecretarySold · $399K · 1,758 sh |
| Jun 1, 2026Form 4 | PYOTT DAVID E IDirectorSold · $1.1M · 3,830 sh · 10b5-1 |
| Apr 6, 2026Form 4 | McLaughlin MelissaChief Human Resources OfficerSold · $755K · 2,286 sh · 10b5-1 |
| Apr 2, 2026Form 4 | McLaughlin MelissaChief Human Resources OfficerSold · $519K · 1,624 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $779K · 2,404 sh · 10b5-1 |
| Mar 5, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $213K · 658 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorSold · $948K · 2,933 sh |
| Mar 4, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerSold · $797K · 2,468 sh |
| Mar 4, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerSold · $746K · 2,309 sh |
| Mar 4, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $746K · 2,309 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $205K · 633 sh · 10b5-1 |
| Mar 3, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $568K · 1,775 sh · 10b5-1 |
| Mar 3, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $528K · 1,652 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorSold · $2.2M · 6,799 sh |
| Mar 2, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerSold · $723K · 2,206 sh |
| Mar 2, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $563K · 1,717 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerSold · $524K · 1,598 sh |
| Mar 2, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $524K · 1,598 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $1.5M · 4,627 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $678K · 2,041 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorSold · $2.2M · 6,958 sh |
| Feb 13, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerSold · $695K · 2,242 sh |
| Feb 13, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $695K · 2,242 sh |
| Feb 13, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $607K · 1,959 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerSold · $607K · 1,959 sh |
| Jan 13, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $848K · 2,290 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorSold · $3.5M · 9,577 sh |
| Jan 12, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerSold · $1.0M · 2,780 sh |
| Jan 12, 2026Form 4 | Garg PushkalEVP Chief R&DSold · $548K · 1,510 sh |
| Jan 12, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchSold · $548K · 1,510 sh · 10b5-1 |
| Jan 12, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerSold · $548K · 1,510 sh |
Awards, exercises, withholding and plan purchases · 57 transactions
| Date | Insider |
|---|---|
| Sep 19, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · $0 · 107 sh |
| Jun 1, 2026Form 4 | Cravatt BenjaminDirectorAward · Stock Option (Right to Buy) · $0 · 4,393 sh |
| Jun 1, 2026Form 4 | PYOTT DAVID E IDirectorExercise or conversion · $0 · 3,830 sh · 10b5-1 |
| Jun 1, 2026Form 4 | PYOTT DAVID E IDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 3,830 sh · 10b5-1 |
| May 20, 2026Form 4 | SCHULMAN AMY WDirectorAward · Stock Option (Right to Buy) · $0 · 1,802 sh |
| May 20, 2026Form 4 | Arbuckle Stuart ADirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | Ausiello Dennis ADirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | HAMBURG MARGARET ADirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | KELLOGG PETER NDirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | PYOTT DAVID E IDirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | Reitan Colleen FDirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | Sigal Charles ElliottDirectorAward · Stock Option (Right to Buy) · $0 · 1,441 sh |
| May 20, 2026Form 4 | SCHULMAN AMY WDirectorAward · $0 · 838 sh |
| May 20, 2026Form 4 | Arbuckle Stuart ADirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | Ausiello Dennis ADirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | BRANDICOURT OLIVIERDirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | HAMBURG MARGARET ADirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | KELLOGG PETER NDirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | PYOTT DAVID E IDirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | Reitan Colleen FDirectorAward · $0 · 671 sh |
| May 20, 2026Form 4 | Sigal Charles ElliottDirectorAward · $0 · 671 sh |
| May 13, 2026Form 4 | SCHULMAN AMY WDirectorExercise or conversion · $790K · 11,250 sh |
| May 13, 2026Form 4 | SCHULMAN AMY WDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 11,250 sh |
| Mar 2, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · Stock Price Performance St… · $0 · 110,746 sh |
| Mar 2, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · Stock Option (right to buy) · $0 · 30,425 sh |
| Mar 2, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · $0 · 13,844 sh |
| Mar 2, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerAward · Stock Option (right to buy) · $0 · 10,480 sh |
| Mar 2, 2026Form 4 | Garg PushkalEVP Chief R&DAward · Stock Option (right to buy) · $0 · 10,480 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerAward · Stock Option (right to buy) · $0 · 10,480 sh |
| Mar 2, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchAward · Stock Option (right to buy) · $0 · 8,105 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerAward · $0 · 4,769 sh |
| Mar 2, 2026Form 4 | Garg PushkalEVP Chief R&DAward · $0 · 4,769 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerAward · $0 · 4,769 sh |
| Mar 2, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchAward · $0 · 3,688 sh · 10b5-1 |
| Mar 2, 2026Form 4 | SUPRAN BRYANEVP, CLO and SecretaryAward · Stock Option (right to buy) · $0 · 3,381 sh |
| Mar 2, 2026Form 4 | SUPRAN BRYANEVP, CLO and SecretaryAward · $0 · 1,539 sh |
| Feb 27, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorExercise or conversion · $0 · 5,921 sh |
| Feb 27, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorExercise or conversion · Restricted Stock Units · $0 · 5,921 sh |
| Feb 27, 2026Form 4 | Garg PushkalEVP Chief R&DExercise or conversion · $0 · 1,908 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Garg PushkalEVP Chief R&DExercise or conversion · Restricted Stock Units · $0 · 1,908 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerExercise or conversion · $0 · 1,908 sh |
| Feb 27, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerExercise or conversion · Restricted Stock Units · $0 · 1,908 sh |
| Feb 27, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerExercise or conversion · $0 · 1,666 sh |
| Feb 27, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerExercise or conversion · Restricted Stock Units · $0 · 1,666 sh |
| Feb 23, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchAward · $0 · 158 sh |
| Feb 12, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · $0 · 14,209 sh |
| Feb 12, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerAward · $0 · 4,579 sh |
| Feb 12, 2026Form 4 | Garg PushkalEVP Chief R&DAward · $0 · 4,579 sh |
| Feb 12, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchAward · $0 · 4,000 sh · 10b5-1 |
| Feb 12, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerAward · $0 · 4,000 sh |
| Jan 11, 2026Form 4 | Greenstreet YvonneChief Executive Officer · DirectorAward · $0 · 19,003 sh |
| Jan 11, 2026Form 4 | Poulton Jeffrey V.EVP, Chief Financial OfficerAward · $0 · 6,193 sh |
| Jan 11, 2026Form 4 | Fitzgerald Kevin JosephCSO & EVP, Head of ResearchAward · $0 · 3,800 sh · 10b5-1 |
| Jan 11, 2026Form 4 | Tanguler TolgaEVP, Chief Commercial OfficerAward · $0 · 3,800 sh |
| Jan 11, 2026Form 4 | Garg PushkalEVP Chief R&DAward · $0 · 3,800 sh |
| Jan 5, 2026Form 4 | Arbuckle Stuart ADirectorAward · Stock Option (right to buy) · $0 · 3,279 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 12 filings
| Filed | What it is |
|---|---|
| Jul 30, 202610-Q | Quarterly report, Q2 2026 — revenue $1.29B (+67% y/y), net income $164.5M, EPS $1.21 |
| Jul 30, 20268-K | Earnings release — EPS $1.21 vs $1.44 est. (−16.0%); revenue $1.29B (+67% y/y) 28.3% |
| May 27, 20268-K | Directors or officers; compensation; Shareholder vote results |
| Apr 30, 202610-Q | Quarterly report, Q1 2026 — revenue $1.17B (+96% y/y), net income $206.0M, EPS $1.51 |
| Apr 30, 20268-K | Earnings release — EPS $1.51 vs $0.91 est. (+65.9%); revenue $1.17B (+96% y/y) 2.8% |
| Apr 6, 2026ARS | Annual report to shareholders |
| Apr 6, 2026DEFA14A | Additional proxy materials |
| Apr 6, 2026DEF 14A | Proxy statement |
| Mar 4, 20268-K | Directors or officers; compensation |
| Feb 12, 202610-K | Annual report, FY2025 — revenue $3.71B (+65% y/y), net income $313.7M, EPS $2.33 |
| Feb 12, 20268-K | Earnings release — EPS $0.82 vs $0.81 est. (+9.3%); revenue $1.10B (+85% y/y) 4.3% |
| Jan 12, 20268-K | Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient ImpactResults of operations |
2025 · 23 filings
| Filed | What it is |
|---|---|
| Dec 11, 20258-K | Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027Other events |
| Dec 3, 20258-K | Alnylam Pharmaceuticals Announces Changes to Board of DirectorsDirectors or officers; compensation |
| Oct 30, 202510-Q | Quarterly report, Q3 2025 — revenue $1.25B (+149% y/y), net income $251.1M, EPS $1.84 |
| Oct 30, 20258-K | Earnings release — EPS $1.84 vs $0.46 est. (+300.0%); revenue $1.25B (+149% y/y) 6.7% |
| Oct 3, 20258-K | Material definitive agreement; New financial obligation |
| Sep 12, 20258-K | Material definitive agreement; New financial obligation; Unregistered sale of equity; Other events |
| Sep 10, 20258-K | Other events |
| Jul 31, 202510-Q | Quarterly report, Q2 2025 — revenue $773.7M (+17% y/y), net income −$72.2M, EPS −$0.55 |
| Jul 31, 20258-K | Earnings release — EPS −$0.52 vs −$0.58 est. (+10.3%); revenue $773.7M (+17% y/y) 15.4% |
| Jun 18, 20258-K | Directors or officers; compensation |
| May 13, 20258-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 1, 202510-Q | Quarterly report, Q1 2025 — revenue $594.2M (+20% y/y), net income −$18.3M, EPS −$0.14 |
| May 1, 20258-K | Financial statements and exhibits |
| Apr 4, 2025DEFA14A | Additional proxy materials |
| Mar 24, 2025ARS | Annual report to shareholders |
| Mar 24, 2025DEFA14A | Additional proxy materials |
| Mar 24, 2025DEF 14A | Proxy statement |
| Mar 21, 20258-K | Other events |
| Mar 14, 2025PRE 14A | Preliminary proxy statement |
| Mar 5, 20258-K | Directors or officers; compensation |
| Feb 13, 202510-K | Annual report, FY2024 — revenue $2.25B (+23% y/y), net income −$278.2M, EPS −$2.18 |
| Feb 13, 20258-K | Financial statements and exhibits |
| Jan 13, 20258-K | Results of operations |
2024 · 15 filings
| Filed | What it is |
|---|---|
| Oct 31, 202410-Q | Quarterly report, Q3 2024 — revenue $500.9M (−33% y/y), net income −$111.6M, EPS −$0.87 |
| Oct 31, 20248-K | Financial statements and exhibits |
| Aug 1, 202410-Q | Quarterly report, Q2 2024 — revenue $659.8M (+107% y/y), net income −$16.9M, EPS −$0.13 |
| Aug 1, 20248-K | Financial statements and exhibits |
| May 20, 20248-K | Shareholder vote results |
| May 2, 202410-Q | Quarterly report, Q1 2024 — revenue $494.3M (+55% y/y), net income −$65.9M, EPS −$0.52 |
| May 2, 20248-K | Financial statements and exhibits |
| Apr 1, 2024ARS | Annual report to shareholders |
| Apr 1, 2024DEFA14A | Additional proxy materials |
| Apr 1, 2024DEF 14A | Proxy statement |
| Mar 4, 20248-K | Directors or officers; compensation |
| Feb 15, 202410-K | Annual report, FY2023 — revenue $1.83B (+76% y/y), net income −$440.2M, EPS −$3.52 |
| Feb 15, 20248-K | Earnings release — EPS −$1.10 vs −$1.20 est. (+8.3%); revenue $439.7M (+31% y/y) 10.2% |
| Jan 19, 20248-K | Directors or officers; compensation |
| Jan 8, 20248-K | Results of operations |
2023 · 19 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202310-Q | Quarterly report, Q3 2023 — revenue $750.5M (+184% y/y), net income $147.8M, EPS $1.15 |
| Aug 3, 202310-Q | Quarterly report, Q2 2023 — revenue $318.8M (+42% y/y), net income −$276.0M, EPS −$2.21 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $319.3M (+50% y/y), net income −$174.1M, EPS −$1.40 |
| Apr 3, 2023ARS | Annual report to shareholders |
| Apr 3, 2023DEFA14A | Additional proxy materials |
| Apr 3, 2023DEF 14A | Proxy statement |
| Feb 23, 202310-K | Annual report, FY2022 — revenue $1.04B (+23% y/y), net income −$1.13B, EPS −$9.30 |
12 current reports (8-K) not listed; the year is on EDGAR.
2022 · 20 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 27, 202210-Q | Quarterly report, Q3 2022 — revenue $264.3M (+41% y/y), net income −$405.9M, EPS −$3.32 |
| Jul 28, 202210-Q | Quarterly report, Q2 2022 — revenue $224.8M (+2% y/y), net income −$277.4M, EPS −$2.29 |
| Apr 28, 202210-Q | Quarterly report, Q1 2022 — revenue $213.3M (+20% y/y), net income −$240.3M, EPS −$2.00 |
| Apr 5, 2022DEFA14A | Additional proxy materials |
| Apr 5, 2022DEF 14A | Proxy statement |
| Feb 10, 202210-K | Annual report, FY2021 — revenue $844.3M (+71% y/y), net income −$852.8M, EPS −$7.20 |
14 current reports (8-K) not listed; the year is on EDGAR.
2021 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 28, 202110-Q | Quarterly report, Q3 2021 — revenue $187.6M (+49% y/y), net income −$204.5M, EPS −$1.72 |
| Aug 3, 202110-Q | Quarterly report, Q2 2021 — revenue $220.6M (+112% y/y), net income −$189.6M, EPS −$1.61 |
| Apr 29, 202110-Q | Quarterly report, Q1 2021 — revenue $177.6M (+79% y/y), net income −$200.3M, EPS −$1.71 |
| Apr 2, 2021DEFA14A | Additional proxy materials |
| Apr 2, 2021DEF 14A | Proxy statement |
| Feb 11, 202110-K | Annual report, FY2020 — revenue $492.9M (+124% y/y), net income −$858.3M, EPS −$7.46 |
9 current reports (8-K) not listed; the year is on EDGAR.
2020 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 5, 202010-Q | Quarterly report, Q3 2020 — revenue $125.9M (+80% y/y), net income −$253.3M, EPS −$2.18 |
| Aug 6, 202010-Q | Quarterly report, Q2 2020 — revenue $104.0M (+133% y/y), net income −$179.2M, EPS −$1.56 |
| May 6, 202010-Q | Quarterly report, Q1 2020 — revenue $99.5M (+199% y/y), net income −$182.2M |
| Mar 24, 2020DEFA14A | Additional proxy materials |
| Mar 23, 2020DEF 14A | Proxy statement |
| Feb 13, 202010-K | Annual report, FY2019 — revenue $219.8M (+193% y/y), net income −$886.1M, EPS −$8.11 |
11 current reports (8-K) not listed; the year is on EDGAR.
2019 · 21 filings — 12 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201910-Q | Quarterly report, Q3 2019 — revenue $70.1M (+3286% y/y), net income −$208.5M |
| Aug 6, 201910-Q | Quarterly report, Q2 2019 — revenue $44.7M (+50% y/y), net income −$219.5M |
| May 2, 201910-Q | Quarterly report, Q1 2019 — revenue $33.3M (+52% y/y), net income −$181.9M |
| Apr 10, 2019DEFA14A | Additional proxy materials |
| Apr 8, 2019DEFA14A | Additional proxy materials |
| Mar 21, 2019DEF 14A | Proxy statement |
| Mar 18, 2019PRER14A | Proxy statements |
| Mar 11, 2019PRE 14A | Preliminary proxy statement |
| Feb 14, 201910-K | Annual report, FY2018 — revenue $74.9M (−17% y/y), net income −$761.5M |
12 current reports (8-K) not listed; the year is on EDGAR.
2018 · 20 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 7, 201810-Q | Quarterly report, Q3 2018 — revenue $2.1M (−88% y/y), net income −$245.3M |
| Aug 2, 201810-Q | Quarterly report, Q2 2018 — revenue $29.9M (+88% y/y), net income −$163.6M |
| May 4, 201810-Q | Quarterly report, Q1 2018 — revenue $21.9M (+16% y/y), net income −$141.2M |
| Mar 23, 2018DEF 14A | Proxy statement |
| Feb 15, 201810-K | Annual report, FY2017 — revenue $89.9M (+91% y/y), net income −$490.9M |
15 current reports (8-K) not listed; the year is on EDGAR.
2017 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 7, 201710-Q | Quarterly report, Q3 2017 — revenue $17.1M, net income −$122.9M |
| Aug 9, 201710-Q | Quarterly report, Q2 2017 — revenue $15.9M, net income −$118.4M |
| May 5, 201710-Q | Quarterly report, Q1 2017 — revenue $19.0M, net income −$107.3M |
| Mar 17, 2017DEF 14A | Proxy statement |
| Feb 15, 201710-K | Annual report, FY2016 — revenue $47.2M, net income −$410.1M |
10 current reports (8-K) not listed; the year is on EDGAR.
2016 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2013 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2012 · 24 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2011 · 22 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2010 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2008 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2007 · 19 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 21 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 8 filings — 6 × 8-K, 2 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 61 filings — 42 × 4, 10 × 144, 4 × SCHEDULE 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 6, 20264 | Insider transaction (Form 4) |
| Oct 2, 2026144 | Notice of proposed sale (Form 144) |
| Sep 22, 20264 | Insider transaction (Form 4) |
| Jun 3, 20264 | Insider transaction (Form 4) |
| Jun 3, 20264 | Insider transaction (Form 4) |
| Jun 3, 20263 | Initial insider holdings (Form 3) |
| Jun 1, 2026144 | Notice of proposed sale (Form 144) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 22, 20264 | Insider transaction (Form 4) |
| May 14, 20264 | Insider transaction (Form 4) |
| May 14, 2026SCHEDULE 13G/A | Other filings |
| May 14, 2026SCHEDULE 13G/A | Other filings |
| May 6, 2026SCHEDULE 13G/A | Other filings |
| Apr 29, 2026SCHEDULE 13G | Other filings |
| Apr 7, 20264 | Insider transaction (Form 4) |
| Apr 7, 20263 | Initial insider holdings (Form 3) |
| Apr 6, 2026144 | Notice of proposed sale (Form 144) |
| Mar 26, 2026SCHEDULE 13G/A | Other filings |
The newest 25 of 61 shown; the full year is on EDGAR.
2025 · 83 filings — 53 × 4, 23 × 144, 2 × SCHEDULE 13G/A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 1, 20254 | Insider transaction (Form 4) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 5, 2025SCHEDULE 13G/A | Other filings |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 3, 2025144 | Notice of proposed sale (Form 144) |
| Sep 22, 20253 | Initial insider holdings (Form 3) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Sep 9, 2025144 | Notice of proposed sale (Form 144) |
| Sep 2, 20254 | Insider transaction (Form 4) |
| Aug 29, 2025144 | Notice of proposed sale (Form 144) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 20254 | Insider transaction (Form 4) |
| Aug 19, 2025144 | Notice of proposed sale (Form 144) |
The newest 25 of 83 shown; the full year is on EDGAR.
2024 · 73 filings — 47 × 4, 11 × 144, 10 × SC 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 13, 20244 | Insider transaction (Form 4) |
| Dec 12, 2024144 | Notice of proposed sale (Form 144) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 20244 | Insider transaction (Form 4) |
| Nov 27, 2024144 | Notice of proposed sale (Form 144) |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 8, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Oct 10, 20244 | Insider transaction (Form 4) |
| Oct 3, 20244 | Insider transaction (Form 4) |
| Oct 3, 20243 | Initial insider holdings (Form 3) |
| Sep 25, 2024UPLOAD | Letter from the SEC staff |
| Aug 22, 20244 | Insider transaction (Form 4) |
| Aug 22, 2024CORRESP | Letter to the SEC |
| Aug 20, 2024144 | Notice of proposed sale (Form 144) |
| Aug 14, 20244 | Insider transaction (Form 4) |
| Aug 12, 2024144 | Notice of proposed sale (Form 144) |
| Aug 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Aug 12, 2024UPLOAD | Letter from the SEC staff |
| Aug 8, 20244 | Insider transaction (Form 4) |
| Aug 6, 2024144 | Notice of proposed sale (Form 144) |
| Aug 2, 20244 | Insider transaction (Form 4) |
| Aug 1, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 73 shown; the full year is on EDGAR.
2023 · 54 filings — 39 × 4, 7 × SC 13G/A, 4 × 144 and 3 other forms
Counted, not listed; the year is on EDGAR.
2022 · 44 filings — 34 × 4, 5 × SC 13G/A, 3 × 3 and 1 other form
Counted, not listed; the year is on EDGAR.
2021 · 52 filings — 42 × 4, 6 × SC 13G/A, 2 × SEC STAFF LETTER and 2 other forms
Counted, not listed; the year is on EDGAR.
2020 · 57 filings — 47 × 4, 5 × SC 13G/A, 1 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2019 · 64 filings — 46 × 4, 8 × SC 13G/A, 5 × CT ORDER and 3 other forms
Counted, not listed; the year is on EDGAR.
2018 · 76 filings — 52 × 4, 10 × SC 13G/A, 4 × CT ORDER and 6 other forms
Counted, not listed; the year is on EDGAR.
2017 · 69 filings — 48 × 4, 7 × SC 13G/A, 4 × 424B5 and 7 other forms
Counted, not listed; the year is on EDGAR.
2016 · 50 filings — 37 × 4, 6 × SC 13G/A, 3 × CT ORDER and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 65 filings — 46 × 4, 6 × SC 13G/A, 2 × 3 and 8 other forms
Counted, not listed; the year is on EDGAR.
2014 · 80 filings — 68 × 4, 3 × 3, 2 × CT ORDER and 5 other forms
Counted, not listed; the year is on EDGAR.
2013 · 51 filings — 36 × 4, 3 × CT ORDER, 2 × 424B5 and 7 other forms
Counted, not listed; the year is on EDGAR.
2012 · 41 filings — 32 × 4, 2 × 3, 2 × 424B5 and 3 other forms
Counted, not listed; the year is on EDGAR.
2011 · 38 filings — 20 × 4, 5 × CT ORDER, 3 × CORRESP and 6 other forms
Counted, not listed; the year is on EDGAR.
2010 · 36 filings — 21 × 4, 4 × 3, 3 × CT ORDER and 7 other forms
Counted, not listed; the year is on EDGAR.
2009 · 30 filings — 17 × 4, 3 × CT ORDER, 3 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2008 · 27 filings — 19 × 4, 3 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 33 filings — 23 × 4, 4 × SC 13G/A, 1 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2006 · 38 filings — 22 × 4, 6 × SC 13G/A, 4 × 424B5 and 6 other forms
Counted, not listed; the year is on EDGAR.
2005 · 49 filings — 30 × 4, 5 × SC 13G, 4 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2004 · 73 filings — 28 × 4, 23 × 3, 5 × S-1/A and 10 other forms
Counted, not listed; the year is on EDGAR.
2002 · 2 filings — 1 × REGDEX, 1 × REGDEX/A
Counted, not listed; the year is on EDGAR.
About this data#
Alnylam Pharmaceuticals Inc. (ALNY) has 1,664 filings on EDGAR going back to 2002: 22 annual reports, 69 quarterly reports and 280 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 12, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Jul 30, 2026, furnished a press release headed “Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress”. Over the last 13 months insiders sold $26.9M in 31 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Alnylam Pharmaceuticals Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ALNY's latest 10-K?
- ALNY's latest annual report, a 10-K, was filed on Feb 12, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ALNY last file an 8-K?
- On Jul 30, 2026 it furnished a press release headed “Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Jul 30, 2026.
- Are ALNY insiders buying or selling?
- Over the last 13 months insiders sold $26.9M in 31 sales and bought nothing on the open market; 57 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: SUPRAN BRYAN (EVP, CLO and Secretary) sold 1,758 shares on Oct 2, 2026 for $399K. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ALNY made?
- 1,664 filings are on EDGAR under the registrant records that have been Alnylam Pharmaceuticals Inc., going back to 2002; 975 of them are insider ownership forms (Forms 3, 4, 5 and 144).